Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia.
Hematide is a synthetic peptide-based erythropoiesis-stimulating agent that is being developed by Affymax Inc and Takeda Pharmaceutical Co Ltd. Hematide is undergoing phase III clinical trials for anemia.
Macdougall
Iain C
IC
King's College Hospital, Renal Unit, Denmark Hill, London SE5 9RS, UK. Iain.Macdougall@kch.nhs.uk
D000740:Anemia / Q000188:drug therapy*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004920:Erythropoiesis / Q000187:drug effects*; D006801:Humans; D010330:Patents as Topic; D010455:Peptides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship
D010455:Peptides; C514771:hematide; D011092:Polyethylene Glycols